Source: Eur Respir J 2011; 38: 1261-1277
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bakke P.S., Rönmark E., Eagan T., Pistelli F., Annesi-Maesano I., Maly M., Meren M., Vermeire† P., Vestbo J., Viegi G., Zielinski J., Lundbäck B.. Recommendations for epidemiological studies on COPD. Eur Respir J 2011; 38: 1261-1277

Member's Comments

No comment yet.

Related content which might interest you: Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly Source: Eur Respir J 2003; 21: 3S-9S Year: 2003 The future of disease monitoring and management: the homework for clinical researchers Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005 Determinants of success Source: Eur Respir J 2011; 38: 1215-1218 Year: 2011 Global burden of COPD: systematic review and meta-analysis Source: Eur Respir J 2006; 28: 523-532 Year: 2006 Epidemiology of COPD: social burden and trends for the future Source: Annual Congress 2006 - PG13 - COPD: from aetiology to management Year: 2006 The role of inflammatory biomarkers and health related quality of life questionnaires in distinction of exacerbation and stable chronic obstructive pulmonary diseases Source: International Congress 2014 – Markers Year: 2014 Misdiagnosed COPD: systematic review and meta-analysis Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care Year: 2007 Longitudinal changes in the nature, severity and frequency of COPD exacerbations Source: Eur Respir J 2003 Dec 01;22(6):931-936 Year: 2003 Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study Source: Eur Respir J 2009; 34: 588 Year: 2009 Prognosis: what is the contribution of inflammation to the decline in lung function in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 COPD exacerbations: definitions and classifications Source: Eur Respir J 2003; 21: 46S-53S Year: 2003 Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis Source: International Congress 2016 – COPD diagnosis and management Year: 2016 An epidemiologic study for chronic obstructive pulmonary disease (COPD) with pre-screening by a questionnaire Source: Eur Respir J 2005; 26: Suppl. 49, 594s Year: 2005 Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice Source: Eur Respir J 2013; 41: 1252-1256 Year: 2013 Respiratory symptoms and CRP among participants of the English longitudinal study of ageing (ELSA) – ageing or occult disease? Source: Annual Congress 2007 - Longitudinal and cross sectional risk factors for COPD Year: 2007 Relationship between lung function impairment and incidence or recurrence of cardiovascular disease in a middle-aged cohort Source: Annual Congress 2007 - Longitudinal and cross sectional risk factors for COPD Year: 2007 Biomarkers in the management of COPD Source: Eur Respir Rev 2009; 18: 96-104 Year: 2009 Stratified medicine: drugs meet genetics Source: Eur Respir Rev 2013; 22: 53-57 Year: 2013 Prevalence of undiagnosed COPD: systematic review and meta-analysis Source: Annual Congress 2007 - Management of COPD: pushing forward the boundaries in primary care Year: 2007 Need for generalized criteria in evaluating the impact of new drugs in clinical trials involving patients suffering from COPD Source: Annual Congress 2006 - Outcomes for COPD pharmacological trials: from lung function to biomarkers Year: 2006